Targeting B10 may improve the prognosis of GC as an adjuvant therapy that increases systemic and specific anticancer immunity to maximize the effects of surgery, chemotherapy, monoclonal antibodies, and immune checkpoint inhibitors. This evidence concerns the gene ENPP3 and gastric cancer.